| Literature DB >> 35269245 |
Akshith Dasari1,2, Jingyi Xue1, Sanjukta Deb1.
Abstract
Large bone defects with limited intrinsic regenerative potential represent a major surgical challenge and are associated with a high socio-economic burden and severe reduction in the quality of life. Tissue engineering approaches offer the possibility to induce new functional bone regeneration, with the biomimetic scaffold serving as a bridge to create a microenvironment that enables a regenerative niche at the site of damage. Magnetic nanoparticles have emerged as a potential tool in bone tissue engineering that leverages the inherent magnetism of magnetic nano particles in cellular microenvironments providing direction in enhancing the osteoinductive, osteoconductive and angiogenic properties in the design of scaffolds. There are conflicting opinions and reports on the role of MNPs on these scaffolds, such as the true role of magnetism, the application of external magnetic fields in combination with MNPs, remote delivery of biomechanical stimuli in-vivo and magnetically controlled cell retention or bioactive agent delivery in promoting osteogenesis and angiogenesis. In this review, we focus on the role of magnetic nanoparticles for bone-tissue-engineering applications in both disease modelling and treatment of injuries and disease. We highlight the materials-design pathway from implementation strategy through the selection of materials and fabrication methods to evaluation. We discuss the advances in this field and unmet needs, current challenges in the development of ideal materials for bone-tissue regeneration and emerging strategies in the field.Entities:
Keywords: SPIONs; bone tissue engineering; magnetic nanoparticles; scaffolds for bone tissue engineering
Year: 2022 PMID: 35269245 PMCID: PMC8911835 DOI: 10.3390/nano12050757
Source DB: PubMed Journal: Nanomaterials (Basel) ISSN: 2079-4991 Impact factor: 5.076
Figure 1Components of a typical MNP.
Figure 2(a) TEM image of core-shell Fe3O4-SiO2 magnetic nanoparticles with good dispersity; (b,c) high-resolution TEM images of core-shell Fe3O4-SiO2 magnetic nanoparticles with obvious Fe3O4 core and silica layer. (unpublished data, Jingyi Xue, 2022).
Figure 3Schematic illustration of how the magnetic field generated from SPIONs can enhance osteogenic differentiation of stem cells through the classical Mitogen-activated protein kinase (MAPK) pathway.
Figure 4Schematic displaying organisation of MNP-labelled cells into cell sheets and assembly into multilayer constructs in presence of an external magnetic field.
A table summarising the various studies that investigated the impact of MNP-incorporated scaffolds on osteogenesis.
| Scaffold Material | MNP Composition | MNP Content within Scaffold | Magnetism Intensity (emu/g) | Osteogenic Impact | Mechanism |
|---|---|---|---|---|---|
| HA and Collagen [ | NI | 2.65% | NI | Enhanced bone maturity in-vivo, identified by improved mechanical properties. | Incongruous magnetic moment created by the distribution of MNPs within the scaffold. |
| PCL [ | Maghemite | 7.9% | NI | Improved cell adhesion, proliferation and osteogenic differentiation (elevated ALP) of MSCs. | MNP incorporation generates a magnetic microenvironment. |
| PCL [ | GdHA | 2.67% | NI | Greater cell attachment, spreading, proliferation and osteogenic differentiation (higher ALP, RUNX2) of MSCs. | Gadolinium released entered cells and promoted cell cycle progression. |
| PCL [ | FeHA | 4.5% | NI | Improved cell growth. | MNP incorporation generates a magnetic microenvironment. |
| PCL [ | Magnetite | 5% | 5%—1.6 | Greater cell adhesion, proliferation and osteogenic differentiation (enhanced cellular mineralisation) of MSCs. | Elevated hydrophilicity improved cell adhesion that facilitated proliferation and differentiation to follow. |
| PCL [ | Magnetite | 5%, 10%, 15%, 20% | 5%—1.0 | Better cell adhesion, spreading, penetration and osteogenic differentiation (ALP, COL-1, OPN, BSP) of MSCs. | MNP incorporation generates a magnetic microenvironment. |
| PCL and PLGA [ | Maghemite | 16.4% | 3.56 | Improved cell adhesion, spreading and osteogenic differentiation (higher ALP, RUNX2, OCN, COL-1 and bone mineralisation) of ADSCs. | Greater hydrophilicity and protein adsorptions facilitate cell attachment. |
| PLLA and PGA [ | Magnetite | 2.5%, 5%, 7.5%, 10% | 2.5%—1.66 | Greater cell adhesion, spreading, proliferation and osteogenic differentiation (ALP) of MG63 cells. | Improved hydrophilicity and magnetic microenvironments facilitate improved cellular activity. |
| PCL and Mesoporous Bioactive glass [ | Magnetite | 5%, 10%, 15% | 5%—3.1 | Increased cell adhesion, proliferation and osteogenic differentiation (elevated ALP, RUNX2, OCN, BMP-2 and COL-1) of MSCs. | Improved hierarchal pore structure. |
| CPC [ | Magnetite | 0.05–5% | 0.1%—0.05 | Greater cell adhesion, spreading, proliferation and osteogenic differentiation (increased ALP) of BMSCs. | Altered surface morphology- change in crystal shape and reduced size increased the surface area for adhesion of proteins involved in cell adhesion. |
| CPC [ | Maghemite | NI | NI | Enhanced cell attachment, spreading, proliferation and osteogenic differentiation (increased ALP, RUNX2, OCN, COL-1) of DPSCs. | Altered surface morphology-reduced crystal size increased the surface area for adhesion of proteins involved in cell adhesion. |
| CPC [ | Maghemite | 1–6% | NI | Improved cell adhesion, spreading, proliferation and osteogenic differentiation (increased ALP, RUNX2, OCN, COL-1) of DPSCs. | Greater hydrophilicity and improved nanostructure facilitated cell adhesion and spreading. |
| Gelatin and Siloxane [ | Magnetite | 1–3% | 1%—0.24 | Greater cell adhesion, proliferation and osteogenic differentiation (greater ALP and mineralisation) of MSCs. | Improved hydrophilicity allowed better cell adhesion. |
| Bioglass and Chitosan [ | SrFe12O19 | 1:7, 1:3 | 1:7–4.44 | Enhanced cell adhesion, spreading, proliferation and osteogenic differentiation (increased ALP, RUNX2, OCN, COL-1, BMP-2) of BMSCs. | Proliferation and osteogenic differentiation are mediated by BMP-2/Smad/RUNX2 pathway upon magnetic stimulation. |
| Chitosan and Collagen [ | Magnetite | NI | 0.025 | Improved cell adhesion, proliferation and osteogenic differentiation (better mineralisation) in pre-osteoblasts. | Improved hierarchical nanostructure- surface roughness and interconnected porosity. This can improve cell adhesion, cell penetration as well as nutrient transfer and flow transportation in the scaffold. |
Abbreviations: NI—Not Included, HA—Hydroxyapatite, PCL—Polycaprolactone, PLGA—Poly(lactic co-glycolic acid), PLLA—Polylactic acid, PGA—Poly(glycolic acid), CPC—Calcium Phosphate cement, GdHA—Gadolinium-doped Hydroxyapatite nanoparticles, FeHA—Iron-doped Hydroxyapatite nanoparticles, BMD—Bone Mineral Density, BVF—Bone Volume Fraction, BV/TV—Bone Volume/Tissue Volume. Magnetite—; Maghemite—.
Figure 5Schematic illustration of the cellular adaptive mechanisms to account for increased free iron produced from SPION degradation, which are upregulated ferratin and ferroportin (indicated by + sign). Diagram also highlights the production of ROS by unbound excess iron.
A table summarising the various studies that investigated the impact of SPION dose on the osteogenic differentiation of stem cells.
| Cell Type | SPION Core-Coating (Name If Given) | SPION Diamete (nm) | SPION Incubation Concentration (μg/mL) | Incubation Period | Iron Content per Cell (pg) | Experiment Duration (Days) | Impact on Osteogenic Differentiation | Other Experiments |
|---|---|---|---|---|---|---|---|---|
| Rat BMSCs [ | Iron oxide- citric acid | 96 | 50 | 72 h | 13 | 14 | Impaired | Reduced cell viability with increasing concentration. |
| Rat ADSCs [ | Iron oxide- citric acid | 96 | 50 | 72 h | 13 | 14 | Impaired | Reduced cell viability with increasing concentration. |
| hMSCs [ | Magnetite- amine (NH3+) | 6 | 50 | 72 h | 200 | 21 | Impaired | Improved cell proliferation. |
| hMSCs [ | Iron oxide- carboxydextran (Ferucarbotran) | 62 | 100 | 60 min | NI | 7 | Impaired | Cell mobilisation was promoted. |
| hMSCs [ | Iron oxide- silica | 4.5 | 50 | 4 days | 4 | 14 | Unaffected | Cell viability and proliferation was unimpacted. |
| hMSCs [ | Magnetite- citric acid | 48 | 100 | 72 h | NI | 14 | Unaffected | Cell viability was unaffected. |
| Canine ADSCs [ | Magnetite | 10 | 50 | 12 h | 28 | 21 | Unaffected | Cell viability and proliferation were unimpacted. |
| hMSCs [ | Magnetite- PDA | 57 | 50 | 24 h | NI | 21 | Unaffected | Cell viability and proliferation were unaffected. |
| hMSCs [ | Iron oxide- citrate | 98 | 25 | 24 h | 70 | NI | Unaffected | No cytotoxicity was observed. |
| hMSCs [ | Iron oxide- dextran (Ferumoxide) | 157 | 500 | 24 h | 26 | NI | Unaffected | No cytotoxicity was observed. |
| hMSCs [ | Maghemite- PSC | 30 | 100 | 72 h | NI | 21 | Promoted | Cell viability was unimpacted. |
| hMSCs [ | Magnetite- silica | 55 | 100 | 24 h | NI | 14 | Promoted | Cell viability and proliferation were unaffected. |
| hMSCs [ | Maghemite- PSC | 30 | 100 | 48 h | 0.9 | 21 | Promoted | Cell viability was unimpacted. |
Magnetite—; Maghemite—. Core was referred to as “Iron oxide” if not mentioned in the study. Abbreviations: PDA—Polydopamine, PSC—polyglucose sorbitol carboxymethyl-ether.